Back

The effect of empagliflozin after acute myocardial infarction in patients with and without diabetes: a pre-specified analysis of the EMPACT-MI trial

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Late breaking clinical trials: drugs and disease management Intervention HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Professor Javed Butler

Baylor Scott & White Health, Dallas (United States of America)

9 More presentations in this session

Presentation thumbnail
Discussant review - EMPACT-MI: A Streamlined, Multicentre, Randomised, Parallel Group, Double-blind Placebo-controlled Superiority Trial to Evaluate the Effect of EMPAgliflozin on Hospitalisation for Heart Failure and Mo
Professor L. Kober (Copenhagen, DK)
Slides Video
Presentation thumbnail
Contemporary guideline-directed medical therapy sequencing and titration in de novo, worsening, and chronic heart failure: first data from the TITRATE-HF study
Professor J. Brugts (Rotterdam, NL)
Slides Video
Presentation thumbnail
Discussant review - The TITRATE-HF study
Professor J. Ezekowitz (Edmonton, CA)
Slides Video
Presentation thumbnail
First implementation results from the Trial for Evaluating Accelerated Guideline-Directed Medical Therapy for Heart Failure
Doctor A. Spahillari (Durham, US)
Slides Video
Presentation thumbnail
Discussant review - TEAM-HF: Implementation Study of Accelerated Heart Failure Guideline-Directed Medical Therapy in a General Cardiology Clinic
Professor J. Celutkiene (Vilnius, LT)
Slides Video

Access the full session

Session thumbnail
Late breaking clinical trials: drugs and disease management
Video

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Cardiorenal effects and safety of initiation of empagliflozin after acute myocardial infarction
thumbnail
Congress Presentation
Where do we stand with SGLT2i post-myocardial infarction?
thumbnail
Congress Presentation
Discussant review - EMPACT-MI: A Streamlined, Multicentre, Randomised, Parallel Group, Double-blind Placebo-controlled Superiority Trial to Evaluate the Effect of EMPAgliflozin on Hospitalisation for Heart Failure and Mo

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources